220 - A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted Norovirus Vaccine VXA-G1.1-NN is Immunogenic, Efficacious, and Reduces Viral Shedding Following Norovirus Challenge

Thursday, October 17, 2024

3:45 PM – 4:00 PM US PT

Location: 404 AB

Co-Author(s)

SG

Susan Greco, MD, MPH

Sr Medical Director
Vaxart, Inc
South San Francisco, California, United States

Co-Author(s)

Becca A. Flitter, PhD, MPH

Senior Scientist
Vaxart Inc
South San Francisco, California, United States
Lam Nguyen, MD (she/her/hers)

Associate Medical Director of Pharmacovigilance
Vaxart Inc
Rancho Palos Verdes, CA, United States
MA

Maria D. Apkarian, BA

Vice President Clinical Operations
Vaxart Inc.
Phoenix, Arizona, United States
EN

Elena D. Neuhaus, n/a

Research Associate II
Vaxart
San Francisco, California, United States
DH

Darreann Carmela Hailey, MS

Vaxart, Inc.
South San Francisco, California, United States

Presenting Author(s)

ST

Sean N. Tucker, PhD

CSO, VP of Research
Vaxart
South San Francisco, California, United States

Slides

Co-Author(s)

JC

James F. Cummings, MD

Chief Medical Officer
VAXART
South San Francisco, California, United States

Disclosure(s):

Susan Greco, MD, MPH: Vaxart, Inc: Stocks/Bonds (Public Company)

Becca A. Flitter, PhD, MPH: Vaxart Inc: Stocks/Bonds (Public Company)

Lam Nguyen, MD: CVS Health: Stocks/Bonds (Public Company); Vaxart: Author is either employed and/or has received stock options from Vaxart as part of this work., Stocks/Bonds (Public Company)

Maria D. Apkarian, BA, N/A: No financial relationships to disclose

Elena D. Neuhaus, n/a: No financial relationships to disclose

Darreann Carmela Hailey, MS: Bionano Genomics: Stocks/Bonds (Public Company); Vaxart, Inc.: Stocks/Bonds (Public Company)

Sean N. Tucker, PhD: Vaxart, Inc.: Grant/Research Support, Ownership Interest, patent, Stocks/Bonds (Public Company)

James F. Cummings, MD: VAXART: Stocks/Bonds (Public Company)